01 Procurement
Tender overview
- Buyer
- NHS Blood and Transplant
- Status
- Complete
- Procurement method
- Competitive flexible procedure
- Category
- services
- CPV classification
- Not supplied
- Tender period
- Not supplied — 20 February 2026
Description
NHS Blood and Transplant (NHSBT) are seeking a provider for Next Generation Sequencing (NGS) QC testing requirements for the Cellular and Molecular Therapies (CMT) directorate, namely the Clinical Biotechnology Centre (CBC). CBC handle a number of products in the production of Advanced Therapeutic Investigational Medicinal Products (ATMPs) and starter material master cell banks (MCBs). These require NGS QC testing services that meet specific regulatory requirements.
This page represents one OCDS contracting process. Notices can be revised over time. Values may be estimates, award values or contract values and should be read with their displayed stage and date.
02 Awards and contracts
Published award records
Next Generation Sequencing Testing (NGS)
- Awarded
- 23 June 2026
- Award value
- £407,200
- Suppliers
- 1
- Signed contract
- Not supplied
03 Organisations
Buyers, suppliers and other parties
NHS Blood and Transplant
500 North Bristol Park, Bristol, UKK12, BS34 7QH, United Kingdom
GB-PPON PDBY-6395-VWBPSGS United Kingdom Limited
Inward Way, Rossmore Business Park, Ellesmere Port, UKD63, CH65 3EN, United Kingdom
GB-PPON PLYM-7548-BZWRCompanies House links appear only for explicit GB-COH identifiers. BritDB does not create company links from a similar name or address.
04 Provenance
Source for this process
Contains public sector information licensed under the Open Government Licence v3.0. Official external links are available only on the source transition page.